• Prof. Peter Soyer

    Prof. Soyer has been diagnosising for MoleMap for 6 years. His vision is to eradicate melanoma and his research is driven by this. “Working with MoleMap provides invaluable insights for our research program of the Dermatology Research Centre of The University of Queensland. I am able to diagnose melanoma in its very early phases and, in addition, learn a lot about the life of moles. Moles are dynamic structures growing and disappearing and of course they are the most important mimickers of melanoma.”

    Prof. Soyer’s research interests include early diagnosis of melanoma (dermoscopy), dermatooncology, dermatopathology and teledermatology. He has over 550 publications and presented nationally and internationally. He is the Co-editor in Chief of the Australasian Journal of Dermatology.

  • Dr. John Adams

    Dr. Adams joined the MoleMap Team 10 years ago and since then MoleMap has become an integral part of his daily work. Dr. Adams passed the International Dermoscopy Diploma with distinction and is a member of the International Dermoscopy Society. He has practiced and taught dermoscopy to hospital staff for 20 years and introduced dermoscopic photography in NZ to record images on 35 mm colour slide film (before digital photography was invented). He has presented a number of papers and posters at International Dermoscopy Congresses and been involved in training programs for melanographers.

    A special interest of Dr. Adams has been the CTC clinic at the Wellington Cancer Centre. This clinic assesses patients with complex nonmelanotic skin cancer problems and he has been the dermatological specialist appointed to this combined clinic since 1977.

  • Dr. Colin Parker

    Dr. Parker has over 20 years in Clinical Dermatology and has been diagnosing for MoleMap for the past year, his interest in working with MoleMap was sparked because of the stimulating link with clinical dermatology. Dr. Parker is based in Adelaide and other interests include Australian Aboriginal health.

  • Dr. Martin Haskett

    Dr. Haskett is a member of the MoleMap Australia Pty Ltd Board of Directors having retired in 2015 after 30 years as a dermatologist with special interests in the detection and treatment of skin cancer and teledermatology. He was a consultant dermatologist for the Victorian Melanoma Service at The Alfred Hospital 2000 – 2014, and a diagnosing dermatologist for MoleMap from 2005 – 2011, He has given many lectures and contributed to several publications on the topics of dermoscopy, melanoma diagnosis and treatment.

New Zealand

  • Dr. Mark Gray

    Dr. Gray is one of the founders of MoleMap and has been diagnosing since its inception. He has published numerous articles in peer-reviewed journals and his special interests include dermatologic surgery, laser surgery, cosmetic medicine and phototherapy. Dr. Gray resides in Auckland with his wife Suzanah. He enjoys being part of MoleMap as it provides “the opportunity to continue learning and contributing to the knowledge base in Dermoscopy and the management of melanoma and non-melanoma skin cancer.”

  • Associate Prof. Amanda Oakley

    Assoc. Prof. Oakley’s is a Honorary Associate Professor in Medicine, Faculty of Medical & Health Science, University of Auckland and Dermatologist at Waikato Hospital and at Tristram Clinic in Hamilton. She is also the Website Manager and Chief Editor of the New Zealand Dermatological Society’s website, DermNetNZ, Assoc. Prof. Oakley has been diagnosing for MoleMap for 11 years; she became involved with MoleMap due to her keen interest in skin lesions “It’s very satisfying when I diagnose a skin cancer, particularly melanoma, at an early stage. The MoleMap imaging program offers a wonderful opportunity for learning, teaching and research.”

    Assoc. Prof. Oakley research interests are in teledermatology, teledermatoscopy and early identification of melanoma. She was also co-editor of the first textbook of teledermatology and has published numerous articles in the medical literature, conducts workshops on dermatoscopy for health practitioners and is a regularly speaks at international events.

  • Dr. Shan Edwards

    Dr. Edwards has more than 24 years experience in the industry and currently works in a busy general dermatology private practices in Christchurch and Ashburton. She has been with MoleMap for more than 16 years and enjoys the role due to the upskilling and dermoscopy opportunities. Dr. Edwards interests include early diagnosis and treatment of melanoma and nonmelanoma skin cancers with a longstanding interest in dermoscopy and she has been involved in a number of pharmaceutical clinical research trials specifically immune modulator treatment of Basal Cell Carcinoma.

  • Associate Prof. Marius Rademaker

    Assoc. Prof. Rademaker has been a specialist dermatologist in Hamilton since 1991. He is involved in several multidisciplinary teams at Waikato Hospital, including specialised melanoma, high risk skin cancer, and transplant services and has been diagnosing for MoleMap for over 10 years. With colleagues he has developed the very succesful virtual lesion service within the District Health Board. He is also an Honorary Associate Professor, Division of Medicine (Auckland Medical School, NZ).

    Assoc. Prof. Rademaker has been involved in a large number of national/international committees including New Zealand Skin Cancer Control Steering Committee, International Transplant Skin Cancer Collaborative, and MelNet andis very active in medical research having published over 150 articles and book chapters in the medical literature.

  • Dr. David Scollay

    Dr. Scollay is a specialist clinical dermatologist in private practice in Auckland and has recently become part of the MoleMap Team. His research interests include skin cancer management and melanoma evidence based medicine.

    He is a member of the Society of Investigative Dermatology and the New Zealand Dermatological Society Incorporate, and International Fellow American Academy of Dermatology.




    *Molemap Internal Audit. Benign to malignant ratio from a sample of 700 recommended excisions from 2010-2013. Sensitivity from documentation of reported missed melanomas.